logo
logo
Atlantic International Corp.

Atlantic International Corp.

NASDAQ•ATLN
CEO: Mr. Jeffrey M. Jagid
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 2021-08-27
Atlantic International Corp., through its subsidiaries, operates as a staffing company servicing the commercial, professional, finance, direct placement, and managed service provider verticals. The company specializes in permanent, temporary, and temporary-to-permanent placement services in various areas, including accounting and finance, administrative and clerical, hospitality, information technology, legal, light industrial, and medical fields. It also provides productivity consulting and workforce management solutions. Atlantic International Corp. was founded in 2018 and is based in Englewood Cliffs, New Jersey.
連絡先情報
270 Sylvan Avenue, Suite 2230, Englewood Cliffs, NJ, 07632, United States
201-899-4470
www.atlantic-international.com
時価総額
$185.96M
PER (TTM)
-1.6
20
配当利回り
--
52週高値
$6.50
52週安値
$1.16
52週レンジ
34%
順位65Top 96.0%
1.6
F-Score
改良版 Piotroski 分析
9年ファンダメンタル
弱い • 1.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2017-2025

財務ダッシュボード

Q3 2025 データ

売上高

$110.13M+2.15%
直近4四半期の推移

EPS

-$0.20+25.00%
直近4四半期の推移

フリーCF

-$1.27M-6.41%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Service revenue net reached $315.833M for nine months, marking a 0.9% increase versus 2024.
Net Loss Significantly Reduced Nine-month net loss $32.283M, significantly reduced by 51.7% compared to the prior year period.
Gross Profit Margin Expansion Gross profit $35.007M, increasing 3.4% driven by successful initiative selling higher margin accounts.
Total Debt Reduction Total debt decreased to $76.386M as of September 30, 2025, down from $80.589M year-end.

リスク要因

Key Debt Instruments Default Term Note and Seller Notes obligations are currently in default status, requiring immediate restructuring efforts.
Future Liquidity Requirements Cash flow insufficient to cover Merger Note maturity of $35.000M due March 31, 2027, requiring new financing.
Stockholder Dilution Potential Future debt or equity financing may cause substantial stockholder dilution if additional capital is required.
Legacy Settlement Contingency Significant accrued liabilities remain for legacy stockholder settlements, with some payments still pending finalization.

見通し

New ABL Facility Capacity New ABL facility provides $342.712K borrowing capacity, expected to fund operations for at least one year.
Debt Restructuring Priority Management actively negotiating to refinance or satisfy Assumed Debt obligations to remove joint liability.
Internal Control Remediation Plan Plans to implement improved internal controls by end of 2025/early 2026 to remediate material weaknesses identified.
New Equity Incentive Plan Approved 2025 Omnibus Equity Incentive Plan reserving 10.0M shares for future grants to employees and non-employees.

同業比較

売上高 (TTM)

Atlantic International Corp.ATLN
$445.38M
+3.8%
Health Catalyst, Inc.HCAT
$316.06M
+4.6%
MDxHealth SAMDXH
$152.99M
+23.5%

粗利益率 (最新四半期)

Orchestra BioMed Holdings, Inc.OBIO
94.3%
+1.2pp
Invivyd, Inc.IVVD
91.7%
+0.4pp
Aclaris Therapeutics, Inc.ACRS
83.7%
+39.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PEPG$466.80M-2.4-84.1%9.2%
CYBN$413.02M-1.8-54.5%15.9%
ACRS$364.04M-2.9-102.8%1.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-5.3%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月27日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月14日|
    売上高: $110.13M+2.2%
    |
    EPS: $-0.20+25.0%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月14日|
    売上高: $102.90M-1.7%
    |
    EPS: $-0.20-89.8%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月14日|
    売上高: $102.81M+2.2%
    |
    EPS: $-0.20+364.0%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月28日|
    売上高: $442.61M+10.3%
    |
    EPS: $-3.68-513.3%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月14日|
    売上高: $107.80M+10.2%
    |
    EPS: $-0.16+220.6%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月14日|
    売上高: $104.64M+17.1%
    |
    EPS: $-1.96+3450.7%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月17日|
    売上高: $100.62M+2.6%
    |
    EPS: $-0.04-41.0%
    不明

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年4月10日|
    売上高: $401.37M-9.1%
    |
    EPS: $-0.60-215.8%
    不明